Previous Section Index Home Page

17 Nov 2003 : Column 593W—continued

Hepatitis C

Lynne Jones: To ask the Secretary of State for Health if he will make a statement on progress in working out the details in relation to his announcement on 29 August that he would establish a financial assistance scheme for people infected with hepatitis C as a result of being given blood products by the NHS. [137747]

Miss Melanie Johnson: We are making every effort to progress the hepatitis C financial assistance scheme as quickly as possible and expect to announce details of the scheme's eligibility criteria and payment structure shortly.


Virginia Bottomley: To ask the Secretary of State for Health what steps he is taking to ensure that there is equal access in different areas to Herceptin. [136283]

17 Nov 2003 : Column 594W

Miss Melanie Johnson: My right hon. Friend, the Secretary of State for Health, has asked the National Cancer Director, Professor Mike Richards, to look at the National Health Service in every region and ensure the cancer drugs and treatments, including herceptin, which have been approved by the National Institute for Clinical Excellence, are available nationally.

Professor Richards will be working with cancer networks and the pharmaceutical industry over the next few months to assess the position and identify and address any underlying variations in prescription rates.

Waiting Lists

Mr. Rosindell: To ask the Secretary of State for Health (1) how many people are waiting for hip replacements in each of the London boroughs; [137324]

Mr. Hutton: The information on specific procedures is not identified in the headline waiting times collected by the Department, which are specialty based.

Information for individual trusts and specialties is available on the Department's website at www.


Chris Grayling: To ask the Secretary of State for Health how much extra funding will be provided to practices to support standards in managing high blood pressure; and what the criteria will be for claiming it. [130111]

Miss Melanie Johnson: The new contract for general medical services (QMS), accepted by general practitioners on 20 June 2003, will significantly benefit patients by improving the quality of care, including the management of high blood pressure, and widening the range of services available at GP surgeries.

Two thirds of the additional investment linked to the GMS contract has been earmarked to reward practices for better services. This funding will be allocated through a new Quality and Outcomes Framework, which sets out a range of indicators relating to the detection, recording and management of patients with high blood pressure. Practices will gain a certain number of points according to their performance against these indicators. A typical practice with average list size achieving all the hypertension points might expect to earn £12,975.

Under the new arrangements for the national health service as outlined in "Shifting the Balance of Power", primary care trusts now allocate funding from their own devolved budgets to deliver national targets and milestones and to meet local priorities. The NHS Planning and Performance Framework target for coronary heart disease (CHD) registers requires that the majority of patients at high risk of CHD, particularly those with hypertension, diabetes and a body mass index

17 Nov 2003 : Column 595W

greater than 30 are covered by systematic treatment regimes, including appropriate advice on diet, physical activity and smoking.

Infant Formula Milk

Mrs. Brooke: To ask the Secretary of State for Health (1) what representations he has received on advertisements for infant formula milk (a) on television and (b) in parents' magazines; [135035]

Miss Melanie Johnson [holding answer 29 October 2003]: I have received some letters and emails within the last year about these subjects in general. The Infant Formula and Follow-on Formula Regulations 1995 control the advertisement and promotion of infant formula milk and breast milk substitutes.


Mr. Amess: To ask the Secretary of State for Health (1) what estimate he has made of the number of patients who are suited to treatment with animal insulin rather than synthetic insulin; [137592]

Ms Rosie Winterton: Data on the number of people using these insulins are not collected. However, the table shows the number of prescription items that were dispensed in the community in England, and their cost, in the 12 months ended June 2003.

Decisions on the most suitable type of insulin should be made by people with diabetes in consultation with their healthcare providers. The Department has received no representations about the suitability of synthetic insulin.

Number of prescription items and net ingredient cost of Insulins that were dispensed in the community in England for the 12 months ending June 2003

Number of prescription items (thousand)Net ingredient cost (£000)
Highly purified animal insulin128.14,217.2
Human sequence (GM Insulin)3,522.0150,528.8
All Insulins3,650.0154,746.0


1. The data is from the Prescription Cost Analysis (PCA) system which covers all prescription items that are dispensed in the community in England. This does not include drugs dispensed in hospitals or private prescriptions.

2. Insulins are those defined in the British National Formulary (BNF) paragraph 6.1.1, "Insulins". Insulin drugs have been grouped into highly purified animal and human sequence (GM) insulin in line with the British National Formulary (BNF).

3. Doctors write prescriptions on a prescription form. Each single item written on the form is counted as a prescription item. The net ingredient cost refers to the cost (which the dispenser is reimbursed) of the drug before discounts and does not include any dispensing costs or fees.

17 Nov 2003 : Column 596W

Mr. Amess: To ask the Secretary of State for Health (1) what evidence he has received on adverse reactions to synthetic insulin among diabetics which were not experienced when animal insulin was used; and if he will make a statement; [137593]

Ms Rosie Winterton: The Committee on Safety of Medicines (CSM) and its Sub-Committee on Pharmacovigilance (SCOP) have kept the safety of synthetic (human) insulins under close review and have considered the available data on a number of occasions. Most recently in 2002, the SCOP considered the findings of an independent review of controlled clinical trial data by the Cochrane Collaboration. The conclusions of the Cochrane review were that there is no difference in the incidence of adverse events between patients on synthetic insulin compared with patients on animal insulins. The SCOP confirmed its previous advice that there is no clear evidence of safety problem specific to human insulin. However, the issue will be reviewed again should further information become available.

The Medicines and Healthcare products Regulatory Agency (MHRA) receives reports of suspected adverse drug reactions (ADRs) via the Yellow Card scheme. The most commonly reported suspected ADRs with both synthetic (human) and animal insulins are disorders of metabolism and nutrition such as hypoglycaemia and hypoglycaemia unawareness, followed by skin and subcutaneous tissue disorder such as injection site reaction. However the reporting of a reaction does not necessarily mean that the drug caused the problem.

A higher number of suspected ADR reports have been received in association with synthetic insulin through the Yellow Card Scheme, however this may reflect the fact that 80 per cent. of patients with Type 1 Insulin Dependent Diabetes Mellitus are estimated to be receiving synthetic insulin in the United Kingdom.

Full guidance on prescribing and use of synthetic insulins, including possible side effects, is provided in the product information for prescribes and patients. This includes warnings about the risk of hypoglycaemia unawareness particularly upon transfer from animal insulins to synthetic insulins. Key prescribing information is also included in the British National Formulary, which is sent by the Department to doctors and pharmacists.

Both human and animal derived insulins are currently available and the MHRA is not aware of any specific plans for the discontinuation of production of animal derived insulins. However, decisions as to the most suitable type of insulin for particular patients are clinical matters and must be made by individual doctors.

17 Nov 2003 : Column 597W

Mr. Amess: To ask the Secretary of State for Health if he will meet representatives of the Insulin Dependent Diabetes Trust to discuss the continued (a) choice between and (b) availability of (i) synthetic and (ii) animal insulin. [137594]

Ms Rosie Winterton: I am not aware of any problems with either the choice between or availability of the various types of insulin. I should, however, be interested to have details of the Insulin Dependent Diabetes Trust's concerns and would be happy for them to write to me in the first instance.

Mr. Amess: To ask the Secretary of State for Health what steps he will take to ensure competition in (a) the manufacture of insulin and (b) the manufacture of different types of insulin for treatment of diabetes; and if he will make a statement. [137596]

Ms Rosie Winterton: The Department, working closely with other bodies such as the NHS Purchasing and Supply Agency and pharmaceutical companies, has arrangements in place to ensure security of supply of medicines.

In addition the Pharmaceutical Price Regulation Scheme aims to:

Finally, the patent system provides considerable incentives for companies to compete in the development of new and innovative medicines.

Next Section Index Home Page